RecruitingPhase 2NCT07791576

Population PK-guided ATG Dosing in Haplo-HSCT

Pharmacokinetic Guided ATG Targeted Dosing Strategy in Unmanipulated Haploidentical Haematopoietic Stem-cell Transplantation

Sponsor

Chinese PLA General Hospital

Enrollment

63 participants

Start Date

May 10, 2025

Study Type

INTERVENTIONAL

Conditions

Hematopoietic Stem Cell Transplantation

Summary

To evaluate the safety and efficacy of a population pharmacokinetics (PK)-guided targeted ATG dosing strategy in haploidentical stem cell transplantation and to observe the GVHD-free, relapse-free survival (GRFS) in the cohort receiving this strategy.

Eligibility

Min Age: 14 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Anti Thymocyte Globulin for people with hematopoietic stem cell transplantation. The study is currently recruiting participants at 1 location. People eligible for this study include aged 14 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAnti Thymocyte Globulin

Population pharmacokinetic formula-guided targeted ATG dosing plus classical GVHD prophylaxis regimen

Locations(1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07791576

Related Trials

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

NCT054364182 locations

Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene Therapy

NCT030002441 location

Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors

NCT073752901 location

HematoCare: Feasibility of a Survivorship Care Plan for Hematologic Cancer Patients Undergoing HSCT

NCT075790651 location

Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children

NCT077252631 location